<DOC>
	<DOCNO>NCT01313377</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Observation watch patient 's condition give treatment symptom appear . It yet know whether give gemcitabine hydrochloride together oxaliplatin effective observation treat patient biliary tract cancer remove surgery . PURPOSE : This randomized phase III trial study give gemcitabine hydrochloride together oxaliplatin see well work compare observation treat patient biliary tract cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Oxaliplatin Observation Treating Patients With Biliary Tract Cancer That Has Been Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare disease-free survival ( DFS ) patient resect biliary tract cancer treat adjuvant gemcitabine hydrochloride oxaliplatin versus clinical observation . - Compare quality life patient . Secondary - Compare overall survival patient . - Determine toxicity chemotherapy patient . - Explore prognostic factor DFS include resection result ( R0 v R1 ) , location primary tumor ( intrahepatic v extrahepatic v gallbladder ) , evolution CA19-9 , lymph node involvement ( N0 vs N+ Nx ) . ( Exploratory ) - Study pathological factor surgical specimen identify main characteristic phenotypic clinicoanatomical biliary tract cancer therapy . ( Exploratory ) - Identify nontumor-associated liver injury factor may facilitate emergence biliary tract cancer . ( Exploratory ) - Identify signal pathway may predict response therapy . ( Exploratory ) - Determine molecular characteristic differentiate tumor accord position biliary tract ( extrahepatic bile duct , intrahepatic cholangiocarcinoma site [ hilar ] , peripheral cholangiocarcinoma vesicle site ) . ( Exploratory ) OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 100 minute day 1 oxaliplatin IV 2 hour day 2 . Treatment repeat every 14 day 12 course . - Arm II : Patients undergo clinical observation every 4 week 5 month . Quality life assess baseline , 3 6 month , follow-up visit . After completion study therapy , patient follow 6 month , every 3 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma intrahepatic bile duct , gallbladder , extrahepatic bile duct Mixed form hepatocholangiocarcinomas include provided cholangiocarcinoma predominant Underwent surgical resection disease ( R0 R1 ) least 4 week 13 week ago Nonmetastatic disease assess abdominal MRI chest xray No cancer pancreas duodenum invade bile duct ampulla Vater PATIENT CHARACTERISTICS : ECOG performance status 02 Hemoglobin ≥ 10 g/dL ( transfusion allow ) ANC ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ Creatinine clearance &gt; 40 mL/min Prothrombin time &gt; 60 % OR INR &lt; 1.5 ( without anticoagulant therapy ) Transaminases ≤ 5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Conjugated bilirubin ≤ 35 μmol/L ( biliary drainage , necessary ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No contraindication oxaliplatin gemcitabine hydrochloride therapy Prior invasive cancer allow provide complete remission ≥ 5 year No concurrent invasive cancer except adequately treat carcinoma situ cervix basal cell carcinoma No severe , unresolved disease No mental illness No HIV positivity No grade 1 angina symptomatic angina ≥ grade 2 No sensitive peripheral neuropathy No uncontrolled diabetes No inability undergo medical test due geographical , social , psychological reason No prisoner patient guardianship No Child B C cirrhosis PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior neoadjuvant chemotherapy radiotherapy No prior organ transplantation No concurrent participation another clinical trial experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>liver intrahepatic biliary tract cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>localize gallbladder cancer</keyword>
</DOC>